[go: up one dir, main page]

AR059964A1 - Metodos para reducir la aglomeracion de proteina - Google Patents

Metodos para reducir la aglomeracion de proteina

Info

Publication number
AR059964A1
AR059964A1 ARP070101104A ARP070101104A AR059964A1 AR 059964 A1 AR059964 A1 AR 059964A1 AR P070101104 A ARP070101104 A AR P070101104A AR P070101104 A ARP070101104 A AR P070101104A AR 059964 A1 AR059964 A1 AR 059964A1
Authority
AR
Argentina
Prior art keywords
methods
protein
aglomeration
reduce protein
formulations
Prior art date
Application number
ARP070101104A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38523027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059964(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR059964A1 publication Critical patent/AR059964A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a métodos para reducir la aglomeracion de una proteína o proteínas en una formulacion y formulaciones de proteínas que tienen propiedades de aglomeracion reducidas. Los métodos y formulaciones descritas en este documento, mantienen la actividad biologica de una proteína e incrementan la vida de anaquel de las formulaciones de proteína.
ARP070101104A 2006-03-20 2007-03-19 Metodos para reducir la aglomeracion de proteina AR059964A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78413006P 2006-03-20 2006-03-20

Publications (1)

Publication Number Publication Date
AR059964A1 true AR059964A1 (es) 2008-05-14

Family

ID=38523027

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101104A AR059964A1 (es) 2006-03-20 2007-03-19 Metodos para reducir la aglomeracion de proteina

Country Status (18)

Country Link
US (1) US20080064856A1 (es)
EP (1) EP1996221A2 (es)
JP (1) JP2009530380A (es)
KR (1) KR20080108554A (es)
CN (1) CN101420972A (es)
AR (1) AR059964A1 (es)
AU (1) AU2007227408A1 (es)
BR (1) BRPI0709059A2 (es)
CA (1) CA2646934C (es)
CR (1) CR10290A (es)
EC (1) ECSP088758A (es)
IL (1) IL194123A0 (es)
MX (1) MX2008011888A (es)
NO (1) NO20083940L (es)
PE (1) PE20080121A1 (es)
RU (1) RU2008137634A (es)
TW (1) TW200806317A (es)
WO (1) WO2007109221A2 (es)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
JP5033798B2 (ja) * 2005-07-02 2012-09-26 アレコー・リミテッド タンパク質を含む安定水系
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20080070230A1 (en) * 2006-06-12 2008-03-20 Wyeth Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions
PE20081610A1 (es) * 2007-01-09 2008-12-09 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos
US20100297081A1 (en) * 2007-12-18 2010-11-25 Huang Yanshan Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009087081A2 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue insulinderivate mit extrem verzögertem zeit-/wirkungsprofil
EP2113564A1 (en) * 2008-05-01 2009-11-04 Arecor Limited Protein formulation
JP6146949B2 (ja) * 2008-06-20 2017-06-21 ノバルティス アーゲー 凝集が低減された免疫グロブリン
JP5694150B2 (ja) 2008-06-20 2015-04-01 ノバルティス アーゲー タンパク質中の高分子結合領域および凝集しやすい領域を同定するための方法およびその使用
JP5364310B2 (ja) * 2008-07-14 2013-12-11 アルフレッサファーマ株式会社 反応性物質が結合した微小粒子の安定化方法および該微小粒子含有試薬
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
MX2011002402A (es) * 2008-09-19 2011-04-05 Hoffmann La Roche Formulacion de anticuerpo novedosa.
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
KR101861295B1 (ko) 2009-06-04 2018-05-25 노파르티스 아게 ＩｇＧ 콘쥬게이션을 위한 자리의 확인 방법
PH12011502708B1 (en) * 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
ES2965209T3 (es) 2009-11-13 2024-04-11 Sanofi Aventis Deutschland Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
EP2531209B1 (en) 2010-02-04 2016-04-20 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
US9795674B2 (en) * 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
CA2792965A1 (en) 2010-04-27 2011-11-03 Scil Technology Gmbh Stable aqueous mia/cd-rap formulations
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
EP2399604A1 (en) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
MX341918B (es) * 2011-01-04 2016-09-07 Archivel Farma Sl Formulación de liposomas adecuada para tratar o prevenir la tuberculosis.
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2012250872B2 (en) * 2011-05-02 2017-07-13 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2550357T3 (es) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013063510A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
AU2012365465B2 (en) 2012-01-12 2017-05-18 Archivel Farma, S.L. MTB-C vaccine against asthma
EA201491898A1 (ru) 2012-04-19 2015-08-31 Опко Байолоджикс Лтд. Варианты оксинтомодулина пролонгированного действия и способы получения указанных вариантов
US10132736B2 (en) * 2012-05-24 2018-11-20 Abbvie Inc. Methods for inspection of protein particles in a liquid beneficial agent
JP6129832B2 (ja) * 2012-05-29 2017-05-17 日本ハム株式会社 食品成分抽出液および抽出方法
US10431325B2 (en) 2012-08-03 2019-10-01 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP3848386A1 (en) 2012-11-20 2021-07-14 OPKO Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
GB2533173A (en) 2013-08-05 2016-06-15 Twist Bioscience Corp De Novo synthesized gene libraries
US20150158926A1 (en) * 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US20150126444A1 (en) * 2013-10-21 2015-05-07 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
EP3177317B1 (en) 2014-08-04 2020-03-18 CSL Limited Factor viii formulation
RU2743295C2 (ru) 2014-12-10 2021-02-16 Опко Байолоджикс Лтд. Способы производства стр-модифицированных полипептидов гормона роста длительного действия
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
EP3310347B1 (en) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
BR112018001761A2 (pt) * 2015-07-30 2018-09-18 Biomarin Pharmaceutical Inc. uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética
AU2016324296A1 (en) 2015-09-18 2018-04-12 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
US11512347B2 (en) 2015-09-22 2022-11-29 Twist Bioscience Corporation Flexible substrates for nucleic acid synthesis
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US11976106B2 (en) 2016-07-11 2024-05-07 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CA3034769A1 (en) 2016-08-22 2018-03-01 Twist Bioscience Corporation De novo synthesized nucleic acid libraries
JP6871364B2 (ja) 2016-09-21 2021-05-12 ツイスト バイオサイエンス コーポレーション 核酸に基づくデータ保存
EP4556433A3 (en) 2017-02-22 2025-08-06 Twist Bioscience Corporation Nucleic acid based data storage
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
GB201703063D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
AU2018234629A1 (en) 2017-03-15 2019-10-17 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
ES2986026T3 (es) * 2017-03-31 2024-11-08 Meiji Seika Pharma Co Ltd Formulación acuosa, formulación acuosa en inyector, agente desagregante de proteínas de anticuerpos y método de desagregación de proteínas de anticuerpos
CN110352201A (zh) 2017-04-03 2019-10-18 免疫医疗公司 用于癌症疗法的抗体药物缀合物的皮下施用
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
KR102784398B1 (ko) 2017-06-12 2025-03-19 트위스트 바이오사이언스 코포레이션 심리스 핵산 어셈블리를 위한 방법
GB2581620A (en) 2017-09-11 2020-08-26 Twist Bioscience Corp GPCR binding proteins and synthesis thereof
GB2583590A (en) 2017-10-20 2020-11-04 Twist Bioscience Corp Heated nanowells for polynucleotide synthesis
JP7158015B2 (ja) 2017-11-09 2022-10-21 国立研究開発法人産業技術総合研究所 ポリペプチドの凝集化抑制方法
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
LT4364724T (lt) 2018-05-10 2026-01-12 Regeneron Pharmaceuticals, Inc. Farmacinės formos, kurių sudėtyje yra didelės koncentracijos vegf receptoriaus sulietas baltymas
EP3814497A4 (en) 2018-05-18 2022-03-02 Twist Bioscience Corporation POLYNUCLEOTIDES, REAGENTS AND METHODS FOR NUCLEIC ACID HYBRIDIZATION
EP3843783A1 (en) * 2018-08-29 2021-07-07 GlaxoSmithKline Intellectual Property Development Limited Methods of preparing stable liquid therapeutic protein compositions
JP2020052012A (ja) * 2018-09-28 2020-04-02 株式会社Ｌｓｉメディエンス 不溶性担体を使用する免疫学的測定試薬
WO2020128499A1 (en) * 2018-12-21 2020-06-25 Arecor Limited Novel composition
CA3124980A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
WO2020176678A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
SG11202109283UA (en) 2019-02-26 2021-09-29 Twist Bioscience Corp Variant nucleic acid libraries for antibody optimization
MA55809B1 (fr) * 2019-05-01 2025-12-31 Novo Nordisk A/S Formulations d'anticorps anti-il-6
EP3987019A4 (en) 2019-06-21 2023-04-19 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
WO2020263777A1 (en) * 2019-06-24 2020-12-30 The Children's Hospital Of Philadelphia Use of srrd in the inhibition of protein aggregation
US20220389082A1 (en) 2019-07-04 2022-12-08 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
KR20220033504A (ko) * 2019-07-11 2022-03-16 타보텍 바이오테라퓨틱스 (홍콩) 리미티드 흉선 기질 림프포이에틴(tslp)-수용체 신호전달을 방해하는 제제
EP4464827A3 (en) 2019-09-23 2025-02-26 Twist Bioscience Corporation Variant nucleic acid libraries for crth2
CA3155630A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
EP4085255A1 (en) * 2020-01-03 2022-11-09 Sarepta Therapeutics, Inc. Methods for analyzing aav capsid proteins
JP2023538669A (ja) * 2020-08-24 2023-09-08 アムジェン インコーポレイテッド Ｂｉｔｅ、二重特異性抗体、及びメチオニンを含む医薬製剤
WO2022099223A2 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
WO2024058201A1 (ja) * 2022-09-16 2024-03-21 国立研究開発法人量子科学技術研究開発機構 放射性医薬組成物の中間体の製造方法、放射性医薬組成物の中間体の精製用キット
CN116559444A (zh) * 2023-05-24 2023-08-08 郑州安图生物工程股份有限公司 幽门螺杆菌IgM抗体磁微粒化学发光检测试剂盒

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
CA2304808C (en) * 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
NZ516664A (en) * 1999-07-15 2003-06-30 Inst Genetics Llc Formulations and compositions for interleukin-11
NZ535205A (en) * 1999-10-04 2006-01-27 Chiron Corp Stabilized liquid interleukin-2 ( IL-2 ) containing pharmaceutical compositions
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
TWI283182B (en) * 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
JP2004521103A (ja) * 2000-12-21 2004-07-15 ネクター セラピューティックス インターロイキン４レセプターの貯蔵安定性粉末組成物
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7051050B2 (en) * 2002-03-19 2006-05-23 Netwrok Appliance, Inc. System and method for restoring a single file from a snapshot
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
CN101912601B (zh) * 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
CN1756559B (zh) * 2003-01-08 2010-04-28 诺华疫苗和诊断公司 稳定的含组织因子通路抑制剂或组织因子通路抑制剂变体的液体组合物
US8338374B2 (en) * 2003-12-23 2012-12-25 Pharmacia Corporation Stable growth hormone liquid formulation
AU2005249232B2 (en) * 2004-06-01 2010-08-05 Ares Trading S.A. Method of stabilizing proteins
UA92146C2 (ru) * 2004-06-01 2010-10-11 Эйрэс Трейдинг С.А. Стабилизированная жидкая композиция, которая содержит интерферон
DOP2006000022A (es) * 2005-01-28 2006-08-15 Wyeth Corp Formulaciones líquidas estabilizadas de polipetidos

Also Published As

Publication number Publication date
IL194123A0 (en) 2011-08-01
PE20080121A1 (es) 2008-03-05
MX2008011888A (es) 2008-09-29
AU2007227408A1 (en) 2007-09-27
CA2646934C (en) 2014-09-23
BRPI0709059A2 (pt) 2011-06-21
WO2007109221A3 (en) 2008-02-21
US20080064856A1 (en) 2008-03-13
CN101420972A (zh) 2009-04-29
KR20080108554A (ko) 2008-12-15
NO20083940L (no) 2008-10-16
WO2007109221A9 (en) 2007-12-06
ECSP088758A (es) 2008-10-31
JP2009530380A (ja) 2009-08-27
WO2007109221A2 (en) 2007-09-27
EP1996221A2 (en) 2008-12-03
CA2646934A1 (en) 2007-09-27
RU2008137634A (ru) 2010-04-27
TW200806317A (en) 2008-02-01
CR10290A (es) 2008-11-26

Similar Documents

Publication Publication Date Title
CR10290A (es) Metodos para reducir la aglomeracion de proteina
CR10442A (es) Formulaciones de pepticuerpos terapeuticos liofilizados
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
DOP2006000179A (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimiento de fabricación y utilización
DK1962886T4 (da) Stabile proteinformuleringer
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
CR8904A (es) Formulaciones estabilizadoras
ECSP088262A (es) Proteínas de fusión de albúmina
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ECSP099514A (es) Antagonistas de activina-actrii y usos para aumentar los niveles de glóbulos rojos
ATE464902T1 (de) Stabile pharmazeutische zubereitungen von montelukast-natrium
GT200800274A (es) Enzima dmo modificada y metodos para su utilización
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
BRPI0519170A8 (pt) formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
GT201200189A (es) Antagonistas de pcsk9
PE20150682A1 (es) Variantes de inmunoglobulinas y sus usos
UA94221C2 (en) Lipocalin protein
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
HN2006035237A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
CY1112992T1 (el) Μεσο καλλιεργειας χωρις ορο για την παρασκευη ανασυνδυασμενων γοναδοτροπινων
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
UY31788A (es) Formulación farmacéutica sólida con liberación retardada

Legal Events

Date Code Title Description
FB Suspension of granting procedure